


Cell Stem Cell

Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance

Graphical Abstract



Authors

Benson M. George, Kevin S. Kao, Hye-Sook Kwon, ..., Kyle M. Loh, Judith A. Shizuru, Irving L. Weissman

Correspondence

irv@stanford.edu

In Brief

Treatment of hematological disorders via donor cell transplantation requires harsh and non-specific conditioning protocols. George et al. report an antibody-based conditioning protocol for HSC engraftment that does not require chemotherapy or irradiation and allows robust hematopoietic reconstitution even with fully mismatched MHC donor cells.

Highlights

- Six antibodies suppress a mouse's HSCs, T cells, and NK cells in 8 days
- Antibody treatment enables HSC transplants without radiation and/or chemotherapy
- Transplants can be performed with fully MHC mismatched donors
- Following HSC transplants, animals tolerate solid organs from the same donor

Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance

Benson M. George,^{1,2} Kevin S. Kao,^{1,2} Hye-Sook Kwon,⁴ Brenda J. Velasco,⁴ Jessica Poyser,⁴ Angela Chen,^{1,3} Alan C. Le,⁴ Akanksha Chhabra,⁴ Cassandra E. Burnett,⁴ Devon Cajuste,¹ Malachia Hoover,¹ Kyle M. Loh,^{1,3} Judith A. Shizuru,^{1,4} and Irving L. Weissman^{1,2,3,5,6,*}

¹Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

²Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

³Department of Developmental Biology and the Stanford-UC Berkeley Stem Cell Institute, Stanford, CA 94305, USA

⁴Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

⁵Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA

⁶Lead Contact

*Correspondence: irv@stanford.edu

<https://doi.org/10.1016/j.stem.2019.05.018>

SUMMARY

Hematopoietic cell transplantation can correct hematological and immunological disorders by replacing a diseased blood system with a healthy one, but this currently requires depleting a patient's existing hematopoietic system with toxic and non-specific chemotherapy, radiation, or both. Here we report an antibody-based conditioning protocol with reduced toxicity and enhanced specificity for robust hematopoietic stem cell (HSC) transplantation and engraftment in recipient mice. Host pre-treatment with six monoclonal antibodies targeting CD47, T cells, NK cells, and HSCs followed by donor HSC transplantation enabled stable hematopoietic system reconstitution in recipients with mismatches at half (haploidentical) or all major histocompatibility complex (MHC) genes. This approach allowed tolerance to heart tissue from HSC donor strains in haploidentical recipients, showing potential applications for solid organ transplantation without immune suppression. Fully mismatched chimeric mice developed antibody responses to nominal antigens, showing preserved functional immunity. These findings suggest approaches for transplanting immunologically mismatched HSCs and solid organs with limited toxicity.

INTRODUCTION

Hematopoietic stem cells (HSCs) can self-renew and give rise to all blood cell lineages when transplanted into a recipient (Spangrude et al., 1988; Baum et al., 1992; Uchida et al., 1998; Majeti et al., 2007; Müller et al., 2012b). For these reasons, hematopoietic cell transplantation (HCT) can be used to replace an individual's diseased blood and immune system. Although HCT is most

commonly performed to treat malignancies (Thomas et al., 1979), it can be a curative approach for other disorders, such as thalassemia, sickle cell anemia, inherited immunodeficiencies, autoimmune diseases, and metabolic storage disorders (Lucarelli et al., 1990; Hoogerbrugge et al., 1995; Weissman, 2000; Neven et al., 2009; Bolaños-Meade et al., 2012; Lv et al., 2017). HCT can also induce immunological tolerance, where tissues from an HSC donor can be transplanted without rejection (Billingham et al., 1953; Weissman, 1966, 1973; Gandy and Weissman, 1998). Therefore, HCT can facilitate transplantation of immunologically mismatched organs without the need for lifelong immune suppression, which is associated with the development of malignancy, disordered hematopoiesis, and life-threatening infection (Engels et al., 2011). However, despite the seemingly diverse applicability of HCT, a lack of suitable donors and the toxicities associated with its conventional administration limit its use. Addressing these barriers could allow practitioners to use HCT much more widely in clinical practice and extend its reach into regenerative medicine.

In most transplant situations, donors and recipients are immunologically matched for the major histocompatibility complex (MHC) genes because they govern rejection of foreign cells (Bix et al., 1991). However, MHC matching of siblings occurs in only 25% of cases, contributing to why many patients do not have a match. Haploidentical transplantation, where donors are matched at half of the MHC loci, is becoming more common but is limited by increased rejection, often requiring high-dose immunosuppression to sustain donor grafts (Beatty et al., 1985). If it were possible to perform haploidentical transplantation with limited toxicity and consistent engraftment, this would significantly expand the availability of donors, theoretically allowing any individual to receive HCT from their parent, child, or half of their siblings. Beyond this, the ability to form mixed donor-host chimeras (Sachs et al., 2014) without MHC matching would enable nearly universal application of HSC transplants and donor specific organ transplant tolerance.

To perform HCT, a recipient's blood system is ablated through a process known as conditioning, which provides both immune suppression and makes HSC niches available for donor




Figure 1. A Monoclonal Antibody Cocktail Can Induce Long-Term Multi-lineage Hematopoietic Reconstitution

(A) Dosing schedule for the 4Ab and 6Ab conditioning regimen, where α refers to antibody.

(B) Haploidentical transplantation schematic using AKRB6F₁ donors and CB6F₁ recipients.

(C) Percentage of animals that are chimeric 14–16 weeks after transplanted 30×10^6 or 3×10^6 haploidentical WBM cells with or without NK cell depletion (pooled data from two replicate experiments, pooled $n = 5-10$).

(D) Donor granulocyte chimerism at 16 weeks following haploidentical transplantation of 3×10^6 WBM or 9×10^3 LSK cells in the setting of 4Ab conditioning or irradiation ($n = 4-5$).

(legend continued on next page)

cell engraftment. Currently, HCT conditioning requires chemotherapy and/or radiation, which can induce life-threatening side effects, such as a period of profound immunosuppression during which the patient is at risk of severe infection, irreversible organ toxicity, veno-occlusive disease, mucositis, and secondary malignancy (Michel et al., 1997; Hartman et al., 1998). Therefore, HCT is used to predominantly treat hematologic malignancies (Passweg et al., 2017), where the benefits of HCT outweigh the associated, potentially fatal, risks. Because of the non-specific nature of conventional conditioning regimens, the safety and risk-benefit ratio of HCT for non-malignant diseases could be considerably improved if more specific agents, such as monoclonal antibodies, could be utilized for conditioning. Various studies and clinical protocols have explored the use of antibodies to condition patients for HCT (Cobbald et al., 1986; Sharabi and Sachs, 1989; Nikolic et al., 2000; Spitzer et al., 2003; Czechowicz et al., 2007; Straathof et al., 2009; Worth et al., 2013; Racine et al., 2014; Chhabra et al., 2016). However, these studies still required the use of chemotherapy and/or radiation or were limited to MHC-matched combinations.

In response to these two major barriers, here we report a strategy to safely engraft MHC-mismatched HSCs without the use of chemotherapy, radiation, or both into immunocompetent recipient mice. In our previous work, we showed that antibody-mediated depletion of host HSCs and T cells could facilitate transplantation of HSCs mismatched for minor histocompatibility antigens (Chhabra et al., 2016). However, transplantation of MHC-mismatched tissues is much more difficult than in MHC-matched situations, partly because of the higher frequency of anti-MHC T cells than minor histocompatibility-reactive T cells and the activity of alloreactive natural killer (NK) cells (Lindahl and Wilson, 1977; Kärre et al., 1986). Therefore, to enable major histocompatibility-mismatched HSC engraftment, we hypothesized that blocking host T cell activation and depleting NK cells would be necessary. We demonstrate that conditioning using six monoclonal antibodies enables mice to receive partially (haploidentical) or fully MHC-mismatched HSCs, permitting blood system replacement and induction of tolerance to mismatched donor organs without dependence on chemotherapy or radiation.

RESULTS

We reasoned that expansion of previously demonstrated antibody-conditioning regimens to deplete critical immune subsets would enable more effective HSC transplantation. To deplete HSCs, we chose an antibody targeting KIT (anti-CD117), a transmembrane protein expressed on HSCs and hematopoietic progenitor cells, and anti-CD47 which blocks a dominant anti-phagocytic signal. This combination results in macrophage-assisted depletion of HSCs (Chhabra et al., 2016). To eliminate

host NK cells, we used a depleting antibody targeting CD122/IL2R β (Tanaka et al., 1993; Seung et al., 2003), which is expressed throughout human and mouse NK cell development (Fathman et al., 2011). To further inhibit T cell-mediated rejection, we used an antibody that blocks the CD40-CD40L axis; CD40L is a co-stimulatory cell surface molecule expressed by activated T cells whose blockade has been shown to aid in tolerance induction (Lederman et al., 1992; Noelle et al., 1992; Markes et al., 1997; Durham et al., 2000; Wekerle et al., 2000). We tested whether combinations of antibodies to these targets (here referred to as 4Ab; Figure 1A), would open HSC niches and provide immunosuppression for donor haploidentical or full MHC mismatch HSC engraftment.

Recipient mice were conditioned with 4Ab using a 9-day treatment scheme (Figure 1A). Haploidentical transplantation was performed using AKR x C57BL/6 F₁ mice (hereafter referred to as AB6F₁) as donors and BALB/c x C57BL/6 F₁ (CB6F₁) mice as recipients (Figure 1B); these mouse strains are matched at the H2^b haplotype but mismatched for H2^k and H2^d. We first transplanted 30 × 10⁶ haploidentical whole bone marrow (WBM) cells into 4Ab-conditioned mice, given that WBM contains T cells and facilitator CD8+ cells that diminish host rejection of the graft (Shizuru et al., 1996; Gandy et al., 1999). Chimerism, defined as the presence of more than 1% of donor cells in peripheral blood lineages, was periodically assessed by measuring expression of donor versus recipient-specific CD45 allelic markers, which are expressed on all nucleated blood cells. Although unconditioned mice did not become chimeric, all 4Ab-conditioned mice developed multi-lineage “mixed” chimerism in that both donor and host blood cells co-existed (Figure S1A). Importantly, chimerism was also observed in the HSC compartment (Figure S1B), indicating that peripheral donor cells were the product of active hematopoiesis rather than long-lived mature cells circulating after transplantation.

We tested permutations of the 4Ab regimen and found that no single antibody alone permitted engraftment (Table S1), whereas 4Ab conditioning induced chimerism in all recipient mice transplanted with haploidentical WBM (Figure S1C). Anti-KIT and anti-CD47 combined with either anti-CD40L or anti-CD122 alone induced chimerism in a fraction of mice (Figure S1C), with anti-CD40L proving to be more effective at increasing chimerism. Because attaining high doses of donor cells can be challenging in the clinical setting (Negrin et al., 2000; Müller et al., 2012b), we attempted to use a 10-fold lower dose of WBM. Because NK cell ablation is critical in low-dose HCT (Westerhuis et al., 2005), we attempted engrafting 3 × 10⁶ WBM cells with and without anti-CD122 conditioning (Table S1). When anti-CD122 was excluded, the percentage of mice that became chimeric significantly decreased at the lower cell dose (Figure 1C).

A major limitation of HCT is graft versus host disease (GvHD), which is mediated by transplanted donor T cells attacking the

(E) Donor granulocyte chimerism following 9 × 10³ haploidentical LSK cell transplantation at 16 weeks in irradiated, 4Ab- and 6Ab-conditioned animals (pooled data from two replicate experiments, pooled n = 5–10).

(F) Transplantation schematic using DBA/1J donors and CB6F₁ recipients.

(G) Donor granulocyte chimerism at 8 weeks following WBM and LSK fully MHC-mismatched transplantation in irradiated, 4Ab- and 6Ab-conditioned animals (n = 5).

The data in (C) represent total percentage; one way ANOVA was performed, where *p ≤ 0.05 and **p ≤ 0.01. Data and error bars in (D), (E), and (G) represent means ± SD; one-way ANOVA was performed, where *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.

host, resulting in potentially lethal organ damage as well as immune deficiency caused by lymphoid organ homing donor T cells (Gallatin et al., 1986; Krensky et al., 1990; Weissman, 2000; Tsao et al., 2009; Müller et al., 2012a). GvHD can be avoided by transplanting purified HSCs, which lack mature T cells (Shizuru et al., 1996; Uchida et al., 1998). However, in MHC-mismatched transplants, purified HSCs are particularly susceptible to host rejection (Shizuru et al., 1996; Gandy and Weissman, 1998). Therefore, after establishing proof of concept in WBM, we attempted transplantation of haploidentical Lineage⁻ Sca1⁺ KIT⁺ (LSK) cells, which are highly enriched for HSCs and multipotent progenitors (Morrison and Weissman, 1994; Kiel et al., 2005). We transplanted 9×10^3 LSK cells, which is the number of LSK cells present within 3×10^6 WBM cells. However, LSK cells failed to engraft 4Ab-conditioned mice (Figure 1D).

WBM populations engraft more robustly than purified HSCs because they contain cell populations that may induce immune suppression by actively attacking host immune cells, secreting immunosuppressive factors, or both (Gandy et al., 1999; Grimes et al., 2004; Nilsson et al., 1997). We have shown previously that transplanting purified HSCs can be achieved by additional immunosuppression to eliminate T cells (Shizuru et al., 1996; Chhabra et al., 2016); therefore, we added anti-CD4 and anti-CD8 depleting antibodies to the 4Ab regimen. The use of this six-antibody cocktail (anti-KIT, anti-CD47, anti-CD40L, anti-CD122, anti-CD4, and anti-CD8; hereafter referred to as 6Ab conditioning; Figure 1A) induced multi-lineage chimerism in recipients transplanted with 9×10^3 haploidentical LSK cells (Figure 1A). Withholding any single antibody from the 6Ab cocktail resulted in fewer chimeric animals and lower chimerism; removal of both anti-CD40L and anti-CD122 antibodies generally prevented any engraftment (Figure S1D). Both 4Ab and 6Ab regimens specifically depleted desired cell types while generally sparing B cells and tissue-resident myeloid cells (Figures S2A–S2D), highlighting the targeted nature of these monoclonal antibodies.

To assess whether antibody conditioning could enable fully MHC-mismatched transplants, we used DBA/1J (H2^q) mice as donors and CB6F₁ (H2^{b/d}) as hosts (Figure 1F). 6Ab conditioning enabled efficient LSK transplantation in all mice, whereas only 40% of 4Ab-conditioned mice receiving WBM achieved chimerism (Figure 1G). These findings were compared with outcomes in irradiated mice that also received fully MHC-mismatched transplants. Although all irradiated CB6F₁ mice transplanted with WBM were chimeric by week 3, 80% died by 9 weeks following transplantation (Figure S2E). Given that the LSK-transplanted radiation-conditioned mice did not succumb and that the WBM-transplanted radiation-conditioned mice were initially engrafted, this lethality is possibly due to GvHD in this strain combination. In summary, 6Ab conditioning enabled engraftment of low doses of both haploidentical and fully MHC-mismatched HSCs without recourse to chemotherapy or radiation.

In chimeric mice, the co-existence of donor and recipient immune systems implied the induction of immune tolerance. However, it was unclear whether this was due to central tolerance, where thymic negative selection prevents the formation of donor-reactive host T cells that can induce rejection (Kappler

et al., 1987; Guidos et al., 1990). To gauge central tolerance in the transplanted mice, we measured the presence of the V β 6 chain of the T cell receptor (TCR), which is reactive to the Mtv-7 provirus-encoding super-antigen expressed by the AKR background (Kanagawa et al., 1989; Guidos et al., 1990; Shizuru et al., 2000). The coexistence of AKR x C57BL/6 (AB6F₁) cells in CB6F₁ mice would likely result from thymic deletion of V β 6⁺ T cells by donor HSC-derived thymic medullary dendritic cells and, possibly, host medullary epithelial cells (Rouse et al., 1979, 1985). Deletion of V β 6⁺ T cells was indeed observed in all chimeric animals receiving antibody conditioning for haploidentical WBM or LSK transplants (Figures 2A and 2B). Thus, both 4Ab and 6Ab antibody conditioning followed by immune system replacement can instill central immunological tolerance to the donor mouse strain.

To test whether this central tolerance through antibody conditioning would allow engraftment of donor-matched solid organs, we transplanted neonatal heart grafts (Gandy and Weissman, 1998) from HSC donor (AB6F₁, which are H2^{k/b}) or third-party (DBA/1J strain, which are homozygous for H2^q) newborn mouse pups into the ear pinna of both naive and 6Ab-conditioned haploidentical transplant chimeras (Figure 2C). Graft survival was measured by visualization of the beating heart graft. In naive, unconditioned and untransplanted mice, both AB6F₁ and DBA/1J hearts failed to beat at 14 days (Figure 2D). In 6Ab-conditioned chimeric mice, AB6F₁ hearts began beating at 14 days and persisted for at least 181 days, whereas DBA/1J hearts were rejected. At 34 days, AB6F₁ hearts were still visible in the pinna, whereas DBA/1J hearts were no longer visible (Figure 2E). H&E and immunofluorescence (IF) analysis indicated troponin⁺ cardiac tissue lacking immune cell infiltrates in the AB6F₁-engrafted pinna; troponin⁺ tissue within the pinna containing DBA/1J hearts was not detectable (Figure 2E). These results indicate that, following antibody conditioning and haploidentical HSC engraftment, tolerance to matched heart grafts is feasible while transplantation immunity against completely foreign tissues is preserved.

Given that 6Ab-conditioned chimeras either share half or no MHC molecules and that adaptive immunity is mediated through MHC recognition, it is important to understand whether T cells of donor origin were re-educated to respond to antigens presented by host MHC. To test functional immunity, which requires interactions between T cells, B cells, and antigen-presenting cells following immunization, we challenged mice following a fully MHC-mismatched HSC transplant with keyhole limpet hemocyanin (KLH). Animals with intact T cell-dependent antibody responses will generate immunoglobulin G (IgG) against KLH. Six weeks after transplant, antibody-conditioned mice were able to generate anti-KLH antibodies (Figure 2F); however, their response lagged behind that of unconditioned, untransplanted mice. Importantly, upon a second challenge 2 weeks later, antibody-conditioned mice were able to generate a secondary IgG antibody responses comparable with control mice (Figure 2F).

DISCUSSION

In sum, here we developed a method to transplant half (haploidentical) and fully MHC-mismatched purified HSCs into immunocompetent animals without the use of chemotherapy,




Figure 2. Antibody-Conditioned Animals Have Intact Immune Systems and Display Tolerance to Matched Organ Grafts

(A and B) Abundance of host $V\beta 6^+$ T cells in peripheral blood following (A) WBM and (B) LSK haploidentical transplantation (pooled data from two replicate experiments, pooled, n = 2–10).

(C) Fetal heart into ear transplantation schematic.

(D) Kaplan-Meier curve showing donor heart survival in haploidentical chimeras (n = 5).

(E) Gross examination, H&E, and IF of representative HSC donor and third-party heart tissue in ears 34 days following tissue transplant in haploidentical chimeras.

(F) Anti-KLH IgG production following KLH immunization six (first challenge) and eight (second challenge) weeks after fully MHC-mismatched HSC transplantation (n = 5).

The data in (D) were subjected to a log-rank (Mantel-Cox) test and yielded p = 0.0002. The data and error bars in (F) represent means \pm SD, and one-way ANOVA was performed, where ****p \leq 0.0001.

radiation, or both. Importantly, use of purified HSCs dramatically reduces the risk of GvHD (Weissman, 2000). If translatable to human patients, this antibody-based conditioning strategy to overcome immunological barriers could both expand the HSC donor pool to enable most recipients to find a HCT match and decrease the often prohibitive risks of conditioning that prevent widespread use of HCT.

Although we have demonstrated the efficacy of antibody conditioning in mice, realizing the potential of such conditioning in humans will require further exploration. Despite the cell type specificity of monoclonal antibodies compared with the pleiotropic action of radiation or chemotherapy, the former is not without toxicity. For instance, an anti-CD40L antibody was found to induce thromboembolic events (Kawai et al., 2000; Robles-Carrillo et al., 2010) in humans by cross-linking platelets. However, this effect was found to be Fc-mediated, and newer anti-CD40L therapies that lack Fc domains or contain an inactive Fc domain (Shock et al., 2015; Xie et al., 2014) have been proven to be immunosuppressive without inducing thrombosis. Therefore, further studies to better understand human expression of the proteins targeted here are needed for clinical translation.

Importantly, the ability to induce immunological tolerance to foreign organs could increase opportunities for all patients requiring lifesaving organ transplants. Today, the donor of an organ, tissue, or HSC transplant is a living or recently deceased person. The ultimate goal of regenerative medicine will be to differentiate a pluripotent (embryonic or induced pluripotent) stem cell line into HSCs and other needed tissue stem cells (such as neural [Uchida et al., 2000], bone and cartilage [Chan et al., 2015], or liver [Wang et al., 2015]) either *in vitro* (Loh et al., 2014, 2016) or *in vivo* within a large animal host such as a pig (Rashid et al., 2014; Yamaguchi et al., 2017). Our approach may enable use of these methods to result in more robust, rapid, and gentler transplant schemes, reducing the burden on an organ donation system that is currently dramatically underserving the patients most in need.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHOD DETAILS
 - Pre-Transplantation Conditioning
 - Graft Preparation and Transplantation
 - Peripheral Blood Analysis
 - Spleen and Bone Marrow Population Analysis
 - Ear-Heart Graft
 - KLH immunization and monitoring of KLH antibody production in serum
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.stem.2019.05.018>.

ACKNOWLEDGMENTS

We thank Agnieszka Czechowicz, Deepta Bhattacharya, and Daniel Kraft for helping to initiate this field while in the laboratory and for discussion of the subject matter that resulted in the paper. We thank Kenneth I. Weinberg, Ryan A. Flynn, and Adam J. Rubin for editorial comments. We thank Linda Quinn, Aaron McCarty, Theresa Storm, Teja Naik, and Steve Jungers for technical assistance. We thank Pauline Chu for providing histological services. We thank Patty Lovelace and Stephen Weber for flow cytometry assistance. This study was supported by the California Institute for Regenerative Medicine (RT3-07683 to I.L.W. and J.A.S.); the Ludwig Cancer Foundation and NIH/NCI Outstanding Investigator Award R35CA220434 (to I.L.W.); NIH Director's Early Independence Award DP5OD024558, the Stanford-UC Berkeley Siebel Stem Cell Institute, the Stanford Beckman Center, Anonymous and DiGenova Families, and a Baxter Foundation Faculty Scholar Award (to K.M.L.); and PHS grant CA09302, awarded by the National Cancer Institute, DHHS (to B.M.G.).

AUTHOR CONTRIBUTIONS

B.M.G. wrote the manuscript. B.M.G., H.-S.K., and A. Chhabra designed experiments. B.M.G., K.S.K., H.-S.K., B.J.V., J.P., M.H., and D.C. performed hematopoietic cell transplants, including conditioning and post-transplant chimerism assessment. B.M.G., A. Chen, and K.M.L. performed and analyzed heart graft studies. A.C.L. and C.E.B. performed data analysis. K.M.L. edited the manuscript. I.L.W. and J.A.S. supervised the project, conceived experiments, and edited the manuscript.

DECLARATION OF INTERESTS

A. Chhabra, J.A.S., B.M.G., and I.L.W. are inventors on one or more patents describing antibody-mediated HSC clearance and engraftment (US20180214524A1, US62/041,989, and US20100226927A1). I.L.W. is a cofounder, director, and stockholder of Forty Seven, Inc., the company that licensed these patents. B.M.G., J.A.S., K.S.K., and A. Chhabra are stockholders in and/or were paid consultants for Forty Seven, Inc., which licensed some of the above-stated patent or patents.

Received: June 4, 2018

Revised: December 14, 2018

Accepted: May 20, 2019

Published: June 13, 2019

REFERENCES

- Baum, C.M., Weissman, I.L., Tsukamoto, A.S., Buckle, A.M., and Peault, B. (1992). Isolation of a candidate human hematopoietic stem-cell population. *Proc. Natl. Acad. Sci. USA* *89*, 2804–2808.
- Beatty, P.G., Cliff, R.A., Mickelson, E.M., Nisperos, B.B., Flournoy, N., Martin, P.J., Sanders, J.E., Stewart, P., Buckner, C.D., Storb, R., et al. (1985). Marrow transplantation from related donors other than HLA-identical siblings. *N. Engl. J. Med.* *313*, 765–771.
- Billingham, R.E., Brent, L., and Medawar, P.B. (1953). Actively acquired tolerance of foreign cells. *Nature* *172*, 603–606.
- Bix, M., Liao, N.S., Zijlstra, M., Loring, J., Jaenisch, R., and Raulet, D. (1991). Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. *Nature* *349*, 329–331.
- Bolaños-Meade, J., Fuchs, E.J., Luznik, L., Lanzkron, S.M., Gamper, C.J., Jones, R.J., and Brodsky, R.A. (2012). HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. *Blood* *120*, 4285–4291.
- Chan, C.K., Seo, E.Y., Chen, J.Y., Lo, D., McArdle, A., Sinha, R., Tevlin, R., Seita, J., Vincent-Tompkins, J., Weara, T., et al. (2015). Identification and specification of the mouse skeletal stem cell. *Cell* *160*, 285–298.
- Chhabra, A., Ring, A.M., Weiskopf, K., Schnorr, P.J., Gordon, S., Le, A.C., Kwon, H.S., Ring, N.G., Volkmer, J., Ho, P.Y., et al. (2016). Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. *Sci. Transl. Med.* *8*, 351ra105.

- Cobbold, S.P., Martin, G., Qin, S., and Waldmann, H. (1986). Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. *Nature* 323, 164–166.
- Czechowicz, A., Kraft, D., Weissman, I.L., and Bhattacharya, D. (2007). Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. *Science* 318, 1296–1299.
- Durham, M.M., Bingaman, A.W., Adams, A.B., Ha, J., Waitze, S.Y., Pearson, T.C., and Larsen, C.P. (2000). Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoablative conditioning. *J. Immunol.* 165, 1–4.
- Engels, E.A., Pfeiffer, R.M., Fraumeni, J.F., Jr., Kasiske, B.L., Israni, A.K., Snyder, J.J., Wolfe, R.A., Goodrich, N.P., Bayakly, A.R., Clarke, C.A., et al. (2011). Spectrum of cancer risk among US solid organ transplant recipients. *JAMA* 306, 1891–1901.
- Fathman, J.W., Bhattacharya, D., Inlay, M.A., Seita, J., Karsunky, H., and Weissman, I.L. (2011). Identification of the earliest natural killer cell-committed progenitor in murine bone marrow. *Blood* 118, 5439–5447.
- Gallatin, M., St John, T.P., Siegelman, M., Reichert, R., Butcher, E.C., and Weissman, I.L. (1986). Lymphocyte homing receptors. *Cell* 44, 673–680.
- Gandy, K.L., and Weissman, I.L. (1998). Tolerance of allogeneic heart grafts in mice simultaneously reconstituted with purified allogeneic hematopoietic stem cells. *Transplantation* 65, 295–304.
- Gandy, K.L., Domen, J., Aguila, H., and Weissman, I.L. (1999). CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. *Immunity* 11, 579–590.
- Grimes, H.L., Schanie, C.L., Huang, Y., Cramer, D., Rezzoug, F., Fugier-Vivier, I., and Ildstad, S.T. (2004). Graft facilitating cells are derived from hematopoietic stem cells and functionally require CD3, but are distinct from T lymphocytes. *Exp. Hematol.* 32, 946–954.
- Guidos, C.J., Danska, J.S., Fathman, C.G., and Weissman, I.L. (1990). T cell receptor-mediated negative selection of autoreactive T lymphocyte precursors occurs after commitment to the CD4 or CD8 lineages. *J. Exp. Med.* 172, 835–845.
- Hartman, A.R., Williams, S.F., and Dillon, J.J. (1998). Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. *Bone Marrow Transplant.* 22, 439–443.
- Hoogerbrugge, P.M., Brouwer, O.F., Bordigoni, P., Ringden, O., Kapaun, P., Ortega, J.J., O'Meara, A., Cornu, G., Souillet, G., Frappaz, D., et al.; The European Group for Bone Marrow Transplantation (1995). Allogeneic bone marrow transplantation for lysosomal storage diseases. *Lancet* 345, 1398–1402.
- Kanagawa, O., Palmer, E., and Bill, J. (1989). The T cell receptor V beta 6 domain imparts reactivity to the Mls-1a antigen. *Cell. Immunol.* 119, 412–426.
- Kappler, J.W., Roehm, N., and Marrack, P. (1987). T cell tolerance by clonal elimination in the thymus. *Cell* 49, 273–280.
- Kärre, K., Ljunggren, H.G., Piontek, G., and Kiessling, R. (1986). Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature* 319, 675–678.
- Kawai, T., Andrews, D., Colvin, R.B., Sachs, D.H., and Cosimi, A.B. (2000). Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. *Nat. Med.* 6, 114.
- Kiel, M.J., Yilmaz, O.H., Iwashita, T., Yilmaz, O.H., Terhorst, C., and Morrison, S.J. (2005). SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* 121, 1109–1121.
- Krensky, A.M., Weiss, A., Crabtree, G., Davis, M.M., and Parham, P. (1990). T-lymphocyte-antigen interactions in transplant rejection. *N. Engl. J. Med.* 322, 510–517.
- Lederman, S., Yellin, M.J., Krichevsky, A., Belko, J., Lee, J.J., and Chess, L. (1992). Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). *J. Exp. Med.* 175, 1091–1101.
- Lindahl, K.F., and Wilson, D.B. (1977). Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. *J. Exp. Med.* 145, 508–522.
- Loh, K.M., Ang, L.T., Zhang, J., Kumar, V., Ang, J., Auyeong, J.Q., Lee, K.L., Choo, S.H., Lim, C.Y., Nichane, M., et al. (2014). Efficient endoderm induction from human pluripotent stem cells by logically directing signals controlling lineage bifurcations. *Cell Stem Cell* 14, 237–252.
- Loh, K.M., Chen, A., Koh, P.W., Deng, T.Z., Sinha, R., Tsai, J.M., Barkal, A.A., Shen, K.Y., Jain, R., Morganti, R.M., et al. (2016). Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types. *Cell* 166, 451–467.
- Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S.M., Muretto, P., and Albertini, F. (1990). Bone marrow transplantation in patients with thalassemia. *N. Engl. J. Med.* 322, 417–421.
- Lv, W., Fan, Z., Huang, F., Xu, N., Xuan, L., GuopanYu, Jiang, Q., Zhou, H., Lin, R., Zhang, X., et al. (2017). Autoimmune hematological diseases following haplo-identical donor hematopoietic stem cell transplant compared with matched sibling and unrelated donor. *Oncotarget* 8, 26505–26514.
- Majeti, R., Park, C.Y., and Weissman, I.L. (2007). Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. *Cell Stem Cell* 1, 635–645.
- Markees, T.G., Phillips, N.E., Noelle, R.J., Shultz, L.D., Mordes, J.P., Greiner, D.L., and Rossini, A.A. (1997). Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. *Transplantation* 64, 329–335.
- Michel, G., Socié, G., Gebhard, F., Bernaudin, F., Thuret, I., Vannier, J.P., Demeocq, F., Leverger, G., Pico, J.L., Rubie, H., et al. (1997). Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation—a report from the Société Française de Greffe de Moelle. *J. Clin. Oncol.* 15, 2238–2246.
- Morrison, S.J., and Weissman, I.L. (1994). The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. *Immunity* 1, 661–673.
- Müller, A.M., Shashidhar, S., Küpper, N.J., Kohrt, H.E., Florek, M., Negrin, R.S., Brown, J.M., and Shizuru, J.A. (2012a). Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. *Proc. Natl. Acad. Sci. USA* 109, 5820–5825.
- Müller, A.M., Kohrt, H.E., Cha, S., Laport, G., Klein, J., Guardino, A.E., Johnston, L.J., Stockerl-Goldstein, K.E., Hanania, E., Juttner, C., et al. (2012b). Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. *Biol. Blood Marrow Transplant.* 18, 125–133.
- Negrin, R.S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., Tierney, K., Hu, W.W., Johnston, L.J., Shizuru, J.A., Stockerl-Goldstein, K.E., et al. (2000). Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. *Biol. Blood Marrow Transplant.* 6, 262–271.
- Neven, B., Leroy, S., Decaluwe, H., Le Deist, F., Picard, C., Moshous, D., Mahlaoui, N., Debré, M., Casanova, J.L., Dal Cortivo, L., et al. (2009). Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. *Blood* 113, 4114–4124.
- Nikolic, B., Zhao, G., Swenson, K., and Sykes, M. (2000). A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT. *Blood* 96, 1166–1172.
- Nilsson, S.K., Dooner, M.S., Tiarks, C.Y., Weier, H.U., and Quesenberry, P.J. (1997). Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. *Blood* 89, 4013–4020.
- Noelle, R.J., Roy, M., Shepherd, D.M., Stamenkovic, I., Ledbetter, J.A., and Aruffo, A. (1992). A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. *Proc. Natl. Acad. Sci. USA* 89, 6550–6554.

- Passweg, J.R., Baldomero, H., Bader, P., Bonini, C., Duarte, R.F., Dufour, C., Gennery, A., Kröger, N., Kuball, J., Lanza, F., et al. (2017). Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. *Bone Marrow Transplant* 52, 811–817.
- Racine, J.J., Wang, M., Zhang, M., and Zeng, D. (2014). Induction of mixed chimerism depletes pre-existing and de novo-developed autoreactive B cells in autoimmune NOD mice. *Diabetes* 63, 2051–2062.
- Rashid, T., Kobayashi, T., and Nakauchi, H. (2014). Revisiting the flight of Icarus: making human organs from PSCs with large animal chimeras. *Cell Stem Cell* 15, 406–409.
- Robles-Carrillo, L., Meyer, T., Hatfield, M., Desai, H., Dávila, M., Langer, F., Amaya, M., Garber, E., Francis, J.L., Hsu, Y.M., and Amirkhosravi, A. (2010). Anti-CD40L immune complexes potentially activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. *J. Immunol.* 185, 1577–1583.
- Rouse, R.V., van Ewijk, W., Jones, P.P., and Weissman, I.L. (1979). Expression of MHC antigens by mouse thymic dendritic cells. *J. Immunol.* 122, 2508–2515.
- Rouse, R.V., Ezine, S., and Weissman, I.L. (1985). Expression of major histocompatibility complex antigens in the thymuses of chimeric mice. *Transplantation* 40, 422–426.
- Sachs, D.H., Kawai, T., and Sykes, M. (2014). Induction of tolerance through mixed chimerism. *Cold Spring Harb. Perspect. Med.* 4, a015529.
- Seung, E., Mordes, J.P., Rossini, A.A., and Greiner, D.L. (2003). Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. *J. Clin. Invest.* 112, 795–808.
- Sharabi, Y., and Sachs, D.H. (1989). Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. *J. Exp. Med.* 169, 493–502.
- Shizuru, J.A., Jerabek, L., Edwards, C.T., and Weissman, I.L. (1996). Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. *Biol. Blood Marrow Transplant.* 2, 3–14.
- Shizuru, J.A., Weissman, I.L., Kernoff, R., Masek, M., and Scheffold, Y.C. (2000). Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. *Proc. Natl. Acad. Sci. USA* 97, 9555–9560.
- Shock, A., Burkly, L., Wakefield, I., Peters, C., Garber, E., Ferrant, J., Taylor, F.R., Su, L., Hsu, Y.M., Hutto, D., et al. (2015). CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. *Arthritis Res. Ther.* 17, 234.
- Spangrude, G.J., Heimfeld, S., and Weissman, I.L. (1988). Purification and characterization of mouse hematopoietic stem cells. *Science* 241, 58–62.
- Spitzer, T.R., McAfee, S.L., Dey, B.R., Colby, C., Hope, J., Grossberg, H., Preffer, F., Shaffer, J., Alexander, S.I., Sachs, D.H., and Sykes, M. (2003). Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. *Transplantation* 75, 1748–1751.
- Straathof, K.C., Rao, K., Eyrich, M., Hale, G., Bird, P., Berrie, E., Brown, L., Adams, S., Schlegel, P.G., Goulden, N., et al. (2009). Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. *Lancet* 374, 912–920.
- Tanaka, T., Kitamura, F., Nagasaka, Y., Kuida, K., Suwa, H., and Miyasaka, M. (1993). Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. *J. Exp. Med.* 178, 1103–1107.
- Thomas, E.D., Buckner, C.D., Clift, R.A., Fefer, A., Johnson, F.L., Neiman, P.E., Sale, G.E., Sanders, J.E., Singer, J.W., Shulman, H., et al. (1979). Marrow transplantation for acute nonlymphoblastic leukemia in first remission. *N. Engl. J. Med.* 301, 597–599.
- Tsao, G.J., Allen, J.A., Logronio, K.A., Lazzaroni, L.C., and Shizuru, J.A. (2009). Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. *Proc. Natl. Acad. Sci. USA* 106, 3288–3293.
- Uchida, N., Tsukamoto, A., He, D., Frieria, A.M., Scollay, R., and Weissman, I.L. (1998). High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. *J. Clin. Invest.* 101, 961–966.
- Uchida, N., Buck, D.W., He, D., Reitsma, M.J., Masek, M., Phan, T.V., Tsukamoto, A.S., Gage, F.H., and Weissman, I.L. (2000). Direct isolation of human central nervous system stem cells. *Proc. Natl. Acad. Sci. USA* 97, 14720–14725.
- Wang, B., Zhao, L., Fish, M., Logan, C.Y., and Nusse, R. (2015). Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver. *Nature* 524, 180–185.
- Weissman, I.L. (1966). Studies on the mechanism of split tolerance in mice. *Transplantation* 4, 565–571.
- Weissman, I.L. (1973). Transfer of tolerance. *Transplantation* 15, 265–269.
- Weissman, I.L. (2000). Stem cells: units of development, units of regeneration, and units in evolution. *Cell* 100, 157–168.
- Wekerle, T., Kurtz, J., Ito, H., Ronquillo, J.V., Dong, V., Zhao, G., Shaffer, J., Sayegh, M.H., and Sykes, M. (2000). Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. *Nat. Med.* 6, 464–469.
- Westerhuis, G., Maas, W.G., Willemze, R., Toes, R.E., and Fibbe, W.E. (2005). Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. *Blood* 106, 2215–2220.
- Worth, A.J., Nikolajeva, O., Chiesa, R., Rao, K., Veys, P., and Amrolia, P.J. (2013). Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis. *Blood* 121, 4966–4968.
- Xie, J.H., Yamniuk, A.P., Borowski, V., Kuhn, R., Susulic, V., Rex-Rabe, S., Yang, X., Zhou, X., Zhang, Y., Gillooly, K., et al. (2014). Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. *J. Immunol.* 192, 4083–4092.
- Yamaguchi, T., Sato, H., Kato-Itoh, M., Goto, T., Hara, H., Sanbo, M., Mizuno, N., Kobayashi, T., Yanagida, A., Umino, A., et al. (2017). Interspecies organogenesis generates autologous functional islets. *Nature* 542, 191–196.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-CD47	BioXCell	RRID: AB_2687806
Rat monoclonal anti-CD117	BioXCell	RRID: AB_2687818
Rat monoclonal anti-CD122	BioXCell	RRID: AB_2687820
Armenian hamster monoclonal anti-CD40L	BioXCell	RRID: AB_1107601
Rat monoclonal anti-CD4	BioXCell	RRID: AB_1107636
Rat monoclonal anti-CD8	BioXCell	RRID: AB_10950145
Rat monoclonal anti-CD3 PE	BioLegend	RRID: AB_312662
Rat monoclonal anti-CD4 PE	BioLegend	RRID: AB_11152678
Rat monoclonal anti-CD5 PE	Thermo Fisher Scientific	RRID: AB_2539168
Rat monoclonal anti-CD8 PE	Thermo Fisher Scientific	RRID: AB_465529
Rat monoclonal anti-B220 PE	Thermo Fisher Scientific	RRID: AB_10371899
Rat monoclonal anti-Gr1 PE	Thermo Fisher Scientific	RRID: AB_10376319
Rat monoclonal anti-Mac1 PE	Thermo Fisher Scientific	RRID: AB_11154207
Rat monoclonal anti-TER199 PE	Thermo Fisher Scientific	RRID: AB_2535273
Rat monoclonal anti-Sca1 PE-Cy7	Thermo Fisher Scientific	RRID: AB_469669
Rat monoclonal anti-CD117 APC	Thermo Fisher Scientific	RRID: AB_469429
Rat monoclonal anti-CD3 APC	Thermo Fisher Scientific	RRID: AB_2536039
Mouse monoclonal anti-CD19 PE-Cy7	BD Biosciences	RRID: AB_394495
Rat monoclonal anti-Gr1 Pacific Blue	Thermo Fisher Scientific	RRID: AB_10376182
Rat monoclonal anti-Mac1 APC-Cy7	BD Biosciences	RRID: AB_396772
Mouse monoclonal anti-CD45.1 FITC	Thermo Fisher Scientific	RRID: AB_2534248
Mouse monoclonal anti-CD45.2 PE	Thermo Fisher Scientific	RRID: AB_2534922
Rat monoclonal anti-Vb6	BioLegend	RRID: AB_2564056
Rat monoclonal anti-CD4 APC	Thermo Fisher Scientific	RRID: AB_11152647
Rat monoclonal anti-CD8 FITC	Thermo Fisher Scientific	RRID: AB_11153636
Mouse monoclonal anti-CD19 PE	Thermo Fisher Scientific	RRID: AB_465579
Mouse monoclonal anti-NK1.1 PE-Cy7	Thermo Fisher Scientific	RRID: AB_469665
Rat monoclonal anti-Mac1 APC-Cy7	Thermo Fisher Scientific	RRID: AB_2534404
Rat monoclonal anti-Gr1 eFluor-450	Thermo Fisher Scientific	RRID: AB_1548788
Rat monoclonal anti-CD150 Pacific Blue	BioLegend	RRID: AB_2187962
Rat monoclonal anti-CD34 FITC	Thermo Fisher Scientific	RRID: AB_465021
Rabbit polyclonal anti-Cardiac Troponin I	Abcam	RRID: AB_869982
Goat polyclonal anti-Rabbit IgG Alexa Fluor 488	Thermo Fisher Scientific	RRID: AB_143165
Chemicals, Peptides, and Recombinant Proteins		
KLH	Sigma-Aldrich	Cat# H7017
Complete Freund's Adjuvant	Sigma-Aldrich	Cat# F5881
Incomplete Freund's Adjuvant	Sigma-Aldrich	Cat# F5506
Diphenhydramine	APP Pharmaceuticals	Cat# 63323066401
Critical Commercial Assays		
KLH IgG (Mouse) ELISA Kit	Abnova	Cat# KA2460
Experimental Models: Organisms/Strains		
CB6F1	Jackson Laboratories	Cat# 100007
DBA/1J	Jackson Laboratories	Cat# 670

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
DBA/1J Untimed Pregnant Mice	Taconic Biosciences	N/A
AKR x C57BL/6 F1 (AB6F1)	Bred in the Weissman Laboratory, Stanford University	N/A
Other		
Lineage Cell Depletion Kit, mouse	Miltenyi Biotec	Cat# 130-110-470

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Irving L. Weissman (irv@stanford.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

For HSC transplantation experiments, CB6F1/J (Jax: 100007) and DBA/1J (Jax: 670) mice were purchased from Jackson laboratories, while AKR/J x C57BL/6 F1 (AB6F1) mice were bred at Stanford University. At the time of transplant, all donors and recipients were 8-12 weeks in age and female unless otherwise noted on [Table S1](#). For ear-heart transplantation, untimed pregnant DBA/1J mice were purchased from Taconic Biosciences. Mice for all experiments were immunocompetent and group housed; littermates of the same sex were randomly assigned to experimental groups. All experiments were performed according to guidelines established by the Stanford University Administrative Panel on Laboratory Animal Care.

METHOD DETAILS

Pre-Transplantation Conditioning

For antibody conditioning, all antibodies were suspended in phosphate buffered saline (PBS) and injected intraperitoneally unless otherwise noted. When antibodies were withheld or animals were not conditioned, equivalent volumes of PBS were given intraperitoneally instead. Day 0 corresponds to the day of transplantation. For anti-CD47 (clone mAP410), mice received 100 μ g on Day -8 and 500 μ g daily from Day -6 through Day -2. For anti-KIT (clone ACK2), which is injected retro-orbitally, 500 μ g was given on Day -6. Thirty minutes prior to anti-KIT injections, mice received 400 μ g of diphenhydramine intraperitoneally. Both anti-CD4 (clone GK1.5) and anti-CD8 (clone YTS169.4) were given as 100 μ g injections daily from Day -2 through Day 0 ([Chhabra et al., 2016](#)). For anti-CD122 (clone Tm- β 1), 250 μ g was given on Day -2 ([Tanaka et al., 1993](#); [Seung et al., 2003](#)). For anti-CD40L (clone MR-1), 500 μ g was given on Day 0 ([Wekerle et al., 2000](#)). Irradiation control mice were exposed to two doses of 6.5Gy X-ray radiation on the day of transplantation.

Graft Preparation and Transplantation

Whole bone marrow was extracted from tibias, femurs, hips, and spines of donor mice. Bones were crushed with a mortar and pestle, filtered, and subsequently underwent red blood cell (RBC) lysis. For LSK cell transplants, RBC lysed whole bone marrow was bound to the Miltenyi Lineage Cell Depletion kit cocktail as per the manufacturer's instructions. Flow-through from the magnetic separation columns was collected and stained in PBS with 2% fetal bovine serum (FBS) and the following antibodies: CD3 PE (clone 17A2; 0.66 μ g/mL final concentration), CD4 PE (clone GK1.5; 0.66 μ g/mL final concentration), CD5 PE (clone 53-7.3; 0.66 μ g/mL final concentration), CD8a PE (clone 53-6.7; 0.66 μ g/mL final concentration), B220 PE (clone RA3-6B2; 0.66 μ g/mL final concentration), Gr-1 PE (clone RB6-8C5; 0.5 μ g/mL final concentration), Mac-1 PE (clone M1/70; 0.5 μ g/mL final concentration), Ter119 PE (clone TER119; 0.66 μ g/mL final concentration), SCA1 Pe-Cy7 (clone D7; 1.0 μ g/mL final concentration), and CD117 APC (clone 2B8; 1.0 μ g/mL final concentration). Propidium iodide was added as a viability stain just prior to sorting on a BD Aria. All cells for transplant were re-suspended at the desired concentration in PBS with 2% FBS. All mice were anesthetized using isoflurane and then transplanted with 100 μ L of cell suspension via retro-orbital injection.

Peripheral Blood Analysis

Mice were periodically bled retro-orbitally into EDTA coated tubes. Blood was then incubated in 1% dextran with 5mM EDTA at 37C for 1 hour. The supernatant from each tube was extracted, lysed, and then stained with the following antibodies for peripheral blood chimerism: CD3 APC (clone 17A2; 2.0 μ g/mL final concentration), CD19 PE-Cy7 (clone eBio103; 2.0 μ g/mL final concentration), Gr-1 eFluor-450 (clone RB6-8C5; 1.0 μ g/mL final concentration), Mac-1 APC-Cy7 (clone M1/70; 1.0 μ g/mL final concentration), CD45.1 FITC (clone A20; 2.0 μ g/mL final concentration), and CD45.2 PE (104; 2.0 μ g/mL final concentration). To assess V β 6 TCR expression, peripheral blood was processed as above and stained with V β 6 APC (RR4-7; 2.0 μ g/mL final concentration). Propidium iodide was added as a viability stain just prior to analysis. Samples were analyzed on a BD Fortessa. Donor versus host chimerism was

distinguished based on CD45 allelic differences. For complete blood counts, 20 μ L of peripheral blood was analyzed on a Heska HemaTrue Veterinary Hematology Analyzer.

Spleen and Bone Marrow Population Analysis

Spleens were harvested from conditioned mice and directly mashed in a 70- μ m filter. Hips, femurs and tibia were crushed as described above for bone marrow analysis. Single cells from spleen and bones were lysed, filtered, and stained with the following antibodies for immune cell analysis: CD4 APC (clone GK1.5; 2.0 μ g/mL final concentration), CD8 FITC (clone 53-6.7; 5.0 μ g/mL final concentration), CD19 PE (clone 1D3; 2.0 μ g/mL final concentration), NK1.1 PE-Cy7 (clone PK136; 2.0 μ g/mL final concentration), Mac-1 APC-Cy7 (clone M1/70; 0.5 μ g/mL final concentration), and Gr1 eFluor-450 (clone RB6-8C5; 1.0 μ g/mL final concentration). For long-term HSC chimerism, cells were stained with the following antibodies: CD3 PE (clone 17A2; 0.66 μ g/mL final concentration), CD4 PE (clone GK1.5; 0.66 μ g/mL final concentration), CD5 PE (clone 53-7.3; 0.66 μ g/mL final concentration), CD8a PE (clone 53-6.7; 0.66 μ g/mL final concentration), B220 PE (clone RA3-6B2; 0.66 μ g/mL final concentration), Gr-1 PE (clone RB6-8C5; 0.5 μ g/mL final concentration), Mac-1 PE (clone M1/70; 0.5 μ g/mL final concentration), Ter119 PE (clone TER119; 0.66 μ g/mL final concentration), SCA1 Pe-Cy7 (clone D7; 1.0 μ g/mL final concentration), CD117 APC (clone 2B8; 1.0 μ g/mL final concentration), CD150 Pacific Blue (clone TC15-12F12.2; 5.0 μ g/mL final concentration), CD34 FITC (clone RAM34; 5.0 μ g/mL final concentration), CD45.1 FITC (clone A20; 2.0 μ g/mL final concentration), and CD45.2 PE (clone 104; 2.0 μ g/mL final concentration). Propidium iodide was added as a viability stain just prior to analysis. Samples were analyzed on a BD Fortessa.

Ear-Heart Graft

Neonatal mice were euthanized 1-2 days after birth and their hearts were harvested and placed in ice cold PBS. Recipient mice were prepared by making a small incision on the dorsal side of their ear near the skull. Afterward, using a trocar, a pouch was created by tunneling from the incision site to the tip of the pinna. Neonatal hearts were delivered at the distal end of the pouch with the trocar. The tunnel was closed by gently pushing the lifted skin back to the dermis. Heart viability was monitored for beating by visualizing the graft through a dissecting microscope. At the noted time points, ears were dissected from representative animals and embedded in optimal cutting temperature (O.C.T.) compound. Tissue was sectioned and stained with hematoxylin and eosin, as well as cardiac troponin I. For troponin staining, sections were blocked with PBS containing 10% FBS for 1 hour, and then stained overnight at 4°C in 0.5% bovine serum albumin (BSA) with 10 μ g/mL of anti-cardiac troponin I antibody. Secondary staining was performed with 10 μ g/mL of goat anti-rabbit IgG Alexa Fluor 488 for 30 minutes, and then subsequently stained with DAPI. Images were collected on a Leica DMI6000B epifluorescence-equipped inverted microscope.

KLH immunization and monitoring of KLH antibody production in serum

KLH (Sigma-Aldrich) were mixed with an equal volume of the complete Freund adjuvant (Sigma-Aldrich) for primary immunization or incomplete Freund adjuvant (Sigma-Aldrich) for secondary immunization to form an emulsion by vortexing in 15 mL tube. KLH emulsion (100 μ g KLH in 100 μ L emulsion/mouse) was intraperitoneally injected into transplanted mice 4 weeks post-transplantation for primary immunization. Two (2) weeks after primary immunization, secondary immunization was performed. Serum was collected by retro-orbital bleeding of KLH-immunized mice 2 weeks after secondary immunization. Anti-KLH antibody titer in the serum was determined using KLH IgG mouse ELISA kit (Abnova) and a SpectraMax i3x plate reader (Molecular Device) according to the manufacturer's instructions.

QUANTIFICATION AND STATISTICAL ANALYSIS

Analyses were performed on GraphPad Prism. One- and two-way ANOVA, log-rank test, and unpaired and multiple t tests were used where appropriate; n signifies the number of animals used.

Cell Stem Cell, Volume 25

Supplemental Information

**Antibody Conditioning Enables MHC-Mismatched
Hematopoietic Stem Cell Transplants
and Organ Graft Tolerance**

Benson M. George, Kevin S. Kao, Hye-Sook Kwon, Brenda J. Velasco, Jessica Poyser, Angela Chen, Alan C. Le, Akanksha Chhabra, Cassandra E. Burnett, Devon Cajuste, Malachia Hoover, Kyle M. Loh, Judith A. Shizuru, and Irving L. Weissman







Figure S1, related to Figures 1 and 2: Peripheral blood and HSC chimerism following antibody conditioning

(a) Peripheral blood donor chimerism in the T cell, B cell, and granulocyte lineages 16 weeks following haploidentical WBM transplant (n=5). (b) Twenty-eight-week haploidentical donor chimerism in the long-term HSC compartment (Lin- KIT+ Sca1+ CD150+ CD34-) following PBS or Ab conditioning (n=5). (c) Donor granulocyte chimerism after haploidentical transplantation at 8-9 weeks following conditioning with permutations of 4Ab (pooled data from two replicate experiments, pooled n=7-9). (d) Donor granulocyte chimerism following exclusion of individual components of the 6Ab cocktail at 16 weeks in haploidentical transplantation (pooled data from two replicate experiments, pooled n=8-10). Data and error bars in (a-d) represent means \pm SD; (a), (c), (d) one way ANOVA reveals *P \leq 0.05, **P \leq 0.01, ***P \leq 0.001, and ****P \leq 0.0001, (b) unpaired t-test reveals P \leq 0.01








Figure S2, related to Figures 1 and 2: Immunodepletion following antibody conditioning and survival following major mismatch transplant

(a-b) CBC following conditioning on Day 0 of the (a) 4Ab and (b) 6Ab conditioning protocol (n=3). (c-d) (c) Peripheral blood subpopulations and (d) splenic subpopulations from animals on Day 0 of the PBS, 4Ab, and 6Ab conditioning protocol (n=3). (e) Overall survival of animals transplanted with either LSK or WBM from fully MHC-mismatched donors using either antibody conditioning or irradiation (n=5). Data and error bars in (a-d) represent means \pm SD; (a-b) multiple t-tests reveal $*P \leq 0.05$, (b-c) two way ANOVA was performed where $*P \leq 0.05$, $**P \leq 0.01$, $***P \leq 0.001$ and $****P \leq 0.0001$, (d) log-rank (Mantel-Cox) test yielded $P = 0.0001$.

Supplemental Table 1, related to Figures 1, 2, S1 and S2. All donor and recipient mice were female unless otherwise noted (*indicates male recipients were used, ** indicates male and female recipients were used).

Donor	Recipient	Mismatch	Conditioning Used	Cell Type	Cell Dose	Number Of Animals	Percentage of Animals Chimeric	Average Granulocyte Chimerism of Chimeric Animals	Timepoint (weeks)
A. Related to Figure 1C									
AKR/J x C57Bl/6 F1 (AB6F1)	Balb/c x C57Bl/6 F1 (CB6F1)	Haploidentical	anti-KIT anti-CD47 anti-CD40L	Whole Bone Marrow	30e6	10	90.00	79.39	14-16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L	Whole Bone Marrow	3e6	10	30.00	32.20	14-16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Whole Bone Marrow	30e6	5	100.00	76.88	14-16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Whole Bone Marrow	3e6	10	90.00	27.38	14-16
B. Related to Figure 1D									
AB6F1	CB6F1	Haploidentical	Irradiation	Whole Bone Marrow	3e6	5	100.00	99.98	16
AB6F1	CB6F1	Haploidentical	Irradiation	Lin-KIT+ Sca-1+	9e3	5	100.00	99.96	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Whole Bone Marrow	3e6	5	80.00	19.05	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Lin-KIT+ Sca-1+	9e3	5	0.00	0.00	16
C. Related to Figure 1E, 2B									
AB6F1	CB6F1	Haploidentical	Irradiation	Lin-KIT+ Sca-1+	9e3	5	100.00	0.00	8
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Lin-KIT+ Sca-1+	9e3	10	10.00	1.56	8
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122 anti-CD4 anti-CD8	Lin-KIT+ Sca-1+	9e3	10	90.00	32.89	8
D. Related to Figure 1G									
DBA/1J	CB6F1	Full	Unconditioned	Whole Bone Marrow	3e6	5	0.00	0.00	8
DBA/1J	CB6F1	Full	anti-KIT anti-CD47 anti-CD40L anti-CD122 anti-CD4 anti-CD8	Whole Bone Marrow	3e6	5	40.00	3.65	8
DBA/1J	CB6F1	Full	anti-KIT anti-CD47 anti-CD40L anti-CD122 anti-CD4 anti-CD8	Lin-KIT+ Sca-1+	9e3	5	100.00	52.40	8
DBA/1J	CB6F1	Full	Irradiation	Whole Bone Marrow	3e6	5	100.00	98	8

DBA/1J	CB6F1	Full	Irradiation	Lin- KIT+ Sca-1+	9e3	5	100.00	96.80	8
E. Related to Figure 2A, S1C									
AB6F1	CB6F1*	Haploidentical	PBS	Whole Bone Marrow	30e6	2	0.00	0.00	8-9
AB6F1	CB6F1*	Haploidentical	anti-CD122	Whole Bone Marrow	30e6	3	0.00	0.00	8-9
AB6F1	CB6F1*	Haploidentical	anti-CD40L	Whole Bone Marrow	30e6	3	0.00	0.00	8-9
AB6F1	CB6F1*	Haploidentical	anti-KIT	Whole Bone Marrow	30e6	3	0.00	0.00	8-9
AB6F1	CB6F1*	Haploidentical	anti-CD47	Whole Bone Marrow	30e6	2	0.00	0.00	8-9
AB6F1	CB6F1**	Haploidentical	anti-KIT anti-CD47	Whole Bone Marrow	30e6	7	0.00	0.00	8-9
AB6F1	CB6F1**	Haploidentical	anti-KIT anti-CD47 anti-CD40L	Whole Bone Marrow	30e6	9	55.56	59.82	8-9
AB6F1	CB6F1**	Haploidentical	anti-KIT anti-CD47 anti-CD122	Whole Bone Marrow	30e6	9	11.11	63.40	8-9
AB6F1	CB6F1**	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Whole Bone Marrow	30e6	9	100.00	56.09	8-9
F. Related to Figure S1A-B									
AB6F1	CB6F1*	Haploidentical	PBS	Whole Bone Marrow	30e6	5	0	0.00	16/28
AB6F1	CB6F1*	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122	Whole Bone Marrow	30e6	5	5	87.78	16/28
G. Related to Figure S1D									
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD122 anti-CD4 anti-CD8	Lin- KIT+ Sca-1+	9e3	10	40.00	40.78	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD4 anti-CD8	Lin- KIT+ Sca-1+	9e3	10	70.00	35.07	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD4 anti-CD8	Lin- KIT+ Sca-1+	9e3	10	10.00	62.3	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122 anti-CD8	Lin- KIT+ Sca-1+	9e3	8	62.50	18.16	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122 anti-CD4	Lin- KIT+ Sca-1+	9e3	9	55.56	11.41	16
AB6F1	CB6F1	Haploidentical	anti-KIT anti-CD47 anti-CD40L anti-CD122 anti-CD4 anti-CD8	Lin- KIT+ Sca-1+	9e3	9	88.89	36.84	16